VANCOUVER, British Columbia, Dec. 8, 2011 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) will be hosting a Research and Development Day on Friday, December 16, 2011, starting at 8:30 a.m. EST / 5:30 a.m. PST in New York City. Bob Butchofsky, QLT’s President and Chief Executive Officer, and Suzanne Cadden, Senior Vice President of Development, will be discussing the Company’s clinical development and regulatory plans for the synthetic retinoid, QLT091001, for the treatment of Leber Congenital Amaurosis and Retinitis Pigmentosa, in addition to the Company’s Punctal Plug Delivery System for the treatment of glaucoma. The meeting will include presentations by experts in the fields of inherited retinal diseases and glaucoma therapy, including: Dr. Alan Bird, Emeritus Professor at London University, Honorary consultant Moorfields Eye Hospital; Dr. Rob Koenekoop, Director, Ocular Genetics Lab at Montreal Children’s Hospital, McGill University; Dr. Alan Robin, Associate Professor of Ophthalmology at Johns Hopkins, and Professor at University of Maryland; and Dr. Bob Williams, Senior Medical Advisor, QLT Inc., and founder of the Taustine Eye Center, Kentucky.
